Blog

  • Defender to drive Wallabies during Lions Tour

    Defender to drive Wallabies during Lions Tour

    Rugby Australia are proud to have Defender driving the Wallabies as an official partner for the Qatar Airways British & Irish Lions Tour —uniting two icons of strength, resilience, and heritage.

    A long-term partnership that continues to celebrate rugby’s rich legacy while inspiring the next generation of players and fans across the globe.

    Rugby and Defender share a deep connection—cast from the same mould, built for endurance, and driven by a spirit of adventure. Just as rugby demands strength and unwavering determination, Defender embodies these qualities in every journey it takes.

    This announcement builds on Defender’s longstanding commitment to the sport, from being a Worldwide Partner of Rugby World Cup 2023 in France to serving as Principal Partner of the Women’s Rugby World Cup 2025 and a long-term supporter of the Wallabies and Australian Rugby.

    Together, Defender and rugby embrace the impossible—and drive forward with purpose.

    Rugby Australia CEO Phil Waugh said: “Like the Wallabies, Defender are a brand who pride themselves on being the very best in their field, so we’re thrilled to have them on board as an official partner of the Lions Series.

    “They’re a long-term supporter of Rugby across the globe and here in Australia and we’re looking forward to continuing our relationship with them moving forward.”

    Managing Director of JLR Australia, Penny Ferguson said: “Defender is proud to play an integral role in the British and Irish Lions tour of Australia.”

    “Our brand shares a deep connection with the spirit of rugby – built on inner strength, team unity, and relentless determination. In 2025, with the Lions tour and the Women’s Rugby World Cup, we’re proud to support the game across multiple dimensions, both in Australia and globally. With the Home Men’s Rugby World Cup on the horizon in 2027, our commitment to the sport continues to grow.”

    This enthusiasm was echoed by Defender’s Global Managing Director, Mark Cameron.

    The Qatar Airways British & Irish Lions Tour of Australia 2025

    Western Force v British & Irish Lions at 5:45pm AWST on Saturday 28 June at Optus Stadium, Perth

    Queensland Reds v British & Irish Lions at 7:45pm AEST on Wednesday 2 July at Suncorp Stadium, Brisbane

    New South Wales Waratahs v British & Irish Lions at 7:45pm AEST on Saturday 5 July at Allianz Stadium, Sydney

    ACT Brumbies v British & Irish Lions at 7:45pm AEST on Wednesday 9 July at GIO Stadium, Canberra

    AUNZ Invitational XV v British & Irish Lions at 7:15pm ACST on Saturday 12 July at Adelaide Oval, Adelaide

    Wallabies v British & Irish Lions at 7:45pm AEST on Saturday July 19 at Suncorp Stadium, Brisbane

    First Nations & Pasifika XV v British & Irish Lions at 7:45pm AEST on Tuesday 22 July at Marvel Stadium, Melbourne

    Wallabies v British & Irish Lions at 7:45pm AEST on Saturday July 26 at Melbourne Cricket Ground, Melbourne

    Wallabies v British & Irish Lions at 7:45pm AEST on Saturday August 2 at Accor Stadium, Sydney


    Continue Reading

  • New study maps cellular fingerprints driving childhood arthritis

    New study maps cellular fingerprints driving childhood arthritis

    A new groundbreaking study by researchers from University of Birmingham, UCL, Great Ormond Street Hospital and Birmingham Children’s Hospital has revealed important clues into what is driving disease in children with arthritis.

    Cutting-edge techniques have allowed scientists for the first time to uncover the unique architecture of cells and signals inside the joint as inflammation takes hold.

    The new study published in Science Translational Medicine looks at arthritis in children, caused by the immune system mistakenly attacking joints. Juvenile idiopathic arthritis affects more than 10,000 children in the UK. It causes swelling, stiffness and pain in the joints over years or decades, leading to damage of the joints and long-term disability. Whilst treatments are available to manage the condition, and in some cases achieve remission, there is no cure. It can take time to find which treatment works for each person. Treatments don’t work in the same way for every child, suggesting there are hidden differences between individuals that we are only beginning to understand.

    Deepening the scientific and clinical community’s understanding of the condition is vital if more effective treatments are to be found, and undertaking biopsies in young children provides a new way forward. Working with families of children with arthritis opened the door to this study, as the families advocated for the potential of the study, agreeing that the procedure would be acceptable to families, especially compared to living with a chronic inflammatory disease.

    In a world first, tiny tissue samples were collected from the joint lining when children were having medicine injected into the joint. These samples were then analysed with advanced imaging and gene-profiling technologies. The fine resolution maps of the joints revealed differences between children of different ages and cell changes in those with more severe disease. These unique cellular fingerprints may help researchers understand why some drugs work better for some children, and not others. The joints of children with arthritis looked significantly different to those with adults, demonstrating the need to understand arthritis in children better. 

    We know how frustrating it can be for families and young people to find a drug that best works for their arthritis. Finding ways to better predict which medicines will be beneficial for a particular child would mean we were able to treat the disease more rapidly and effectively. To achieve this goal, we first needed to understand what cells make-up the lining of the joint where the inflammation occurs.


    Equipped with that knowledge, we can now start to tackle the next challenge, determining how these cellular fingerprints within the joint tissue can help us predict which drug will work best, ensuring we give the right drug, to the right child, at the right stage of their disease.” 


    Professor Adam Croft, Versus Arthritis Professor of Rheumatology at the University of Birmingham and chief investigator of the study

    One of the children who took part in the study was Aurelia, from London, who was diagnosed with arthritis after injuring her knee while on holiday.

    “Aurelia is a sporty child and loves art, drama, music and ballet. We noticed pain and swelling of her knee whilst on holiday. We thought perhaps she had injured it playing, but when this didn’t get better and she was struggling to walk, we realised something else was wrong. She was referred to the Rheumatology team at Great Ormond Street Hospital who diagnosed her with arthritis. This came as a bit of a shock given how active she is!

    “They offered her a steroid injection in her knee under general anesthetic to alleviate the symptoms. The team asked if we were happy for her to take part in this research study and collect some tissue samples at the same time.

    “We were keen for her to be involved, as there’s still a lot of unknowns with arthritis in children, and not all treatments can work. Given that she was already having an anaesthetic, and it wasn’t an additional operation for her, it was a great opportunity for researchers to take samples and to be better able to study the conditions. We hope the study will help other families with children in similar positions to us,” explained Aurelia’s mum, Emily.

    Professor Lucy Wedderburn, University College London Great Ormond Street Institute of Child Health and Consultant of Paediatric Rheumatology at Great Ormond Street Hospital said:

    “This study represents a real step change in our work with children and young people who live with arthritis, and has been a huge team effort. Rather than having to rely on blood tests which often do not tell us accurately what is happening in the joint, we can now directly analyse the joint lining, across different types of childhood arthritis and different ages. Our findings show that younger children have different types of immune cells invading their joints compared to older children. Samples from children with arthritis looked different to adult samples, with a different make up of immune cells, blood vessels and distinct connective tissue cells. This suggests that treatments may need to vary depending on age and shows why we can’t just extend studies from adult studies to understand arthritis in children.”

    The study was funded by the Medical Research Council, Versus Arthritis, National Institute of Health and Care Research, Great Ormond Street Hospital Charity, amongst others, and delivered through the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC).

    Lucy Donaldson, Director of Research at Versus Arthritis said:

    “People with arthritis should never be reduced to just their condition. Each person deserves to be treated holistically as an individual, including, of course, children and young people with arthritis.

    “We are very proud to invest in truly innovative research like the MAPJAG study which is helping us to better understand the individual differences between young people with juvenile arthritis.

    “The MAPJAG team’s findings clearly show that children and young people aren’t just small adults, but have a different “cellular fingerprint”. Importantly the team have also shown that this can change with age. The findings can give real hope to all those families that more can be done, sooner, to enable young people with arthritis to live the lives they choose.” 

    A wider programme of work, made possible by a Medical Research Council partnership award known as Tissue Research in Childhood Arthritis (TRICIA), supports the infrastructure needed for multi-centre tissue research of the joint. In future, it is hoped that a larger study, involving more centres will allow researchers to dig deeper into the remaining questions about how best to tailor treatments for individual patients.

    Instrumental to driving this research forward was Dr Eslam Al-Abadi, a study investigator from the Birmingham Women’s and Children’s Hospital NHS Foundation Trust, who sadly passed away before publication. His incredible efforts in seeking to improve the care of children with this disease are gratefully acknowledged.

    Source:

    Journal reference:

    Bolton, C., et al. (2025) Synovial tissue atlas in juvenile idiopathic arthritis reveals pathogenic niches associated with disease severity. Science Translational Medicine. doi.org/10.1126/scitranslmed.adt6050.

    Continue Reading

  • New protein target offers hope for chronic inflammation treatment

    New protein target offers hope for chronic inflammation treatment

    Chronic inflammation occurs when the immune system is stuck in attack-mode, sending cell after cell to defend and repair the body for months or even years. Diseases associated with chronic inflammation, like arthritis or cancer or autoimmune disorders, weigh heavily on human health-and experts anticipate their incidence is on the rise. A new study by investigators from Mass General Brigham identified a protein called WSTF that could be targeted to block chronic inflammation. Crucially, this strategy would not interfere with acute inflammation, allowing the immune system to continue responding appropriately to short-term threats, such as viral or bacterial infection. Results are published in Nature.

    Chronic inflammatory diseases cause a great deal of suffering and death, but we still have much to learn about what drives chronic inflammation and how to treat it. Our findings help us separate chronic and acute inflammation, as well as identify a new target for stopping chronic inflammation that results from aging and disease.”


    Zhixun Dou, PhD, senior author of the Center for Regenerative Medicine and Krantz Family Center for Cancer Research at Massachusetts General Hospital

    Using chronically inflamed human cells, the researchers found that WSTF interacts with other proteins inside cell nuclei, which prompts its excretion and degradation. Since WSTF is responsible for concealing pro-inflammatory genes, this nucleus-eviction reveals those genes and, in turn, amplifies inflammation. They confirmed that WSTF loss could promote inflammation in mouse models of aging and cancer. They also found, using human cells, that WSTF loss only occurred in chronic inflammation, not acute. Using these findings, the researchers designed a WSTF-restoring therapeutic to suppress chronic inflammation and observed preliminary success in mouse models of aging, metabolic dysfunction-associated steatohepatitis (MASH), and osteoarthritis.

    The researchers went further to examine tissue samples from patients with MASH or osteoarthritis. They found that WSTF is lost in the livers of patients with MASH, but not in the livers of healthy donors. Using cells from the knees of osteoarthritis patients undergoing joint replacement surgery, they showed that WSTF-restoring therapeutic reduces chronic inflammation from the inflamed knee cells. These findings highlight the potential of developing new treatments targeting WSTF to combat chronic inflammatory diseases.

    Further research is needed to validate the therapeutic potential of WSTF restoration in broader settings and to develop specific strategies to target WSTF. Additionally, the findings suggest other similar proteins may be involved in chronic inflammation, opening a promising new avenue for studying and treating inflammation in the future.

    Source:

    Journal reference:

    Wang, Y., et al. (2025). WSTF nuclear autophagy regulates chronic but not acute inflammation. Nature. doi.org/10.1038/s41586-025-09234-1.

    Continue Reading

  • UF students are bending metal with lasers to build massive structures in orbit

    UF students are bending metal with lasers to build massive structures in orbit

    In the vast vacuum of space, Earth-bound limitations no longer apply. And that’s exactly where UF engineering associate professor Victoria Miller, Ph.D., and her students are pushing the boundaries of possibilities.

    In partnership with the Defense Advanced Research Projects Agency, known as DARPA, and NASA’s Marshall Space Flight Center, the University of Florida engineering team is exploring how to manufacture precision metal structures in orbit using laser technology.

    “We want to build big things in space. To build big things in space, you must start manufacturing things in space. This is an exciting new frontier,” said Miller.

    An associate professor in the Department of Materials Science & Engineering at UF’s Herbert Wertheim College of Engineering, Miller said the project called NOM4D – which means Novel Orbital and Moon Manufacturing, Materials, and Mass-efficient Design – seeks to transform how people think about space infrastructure development. Picture constructing massive structures in orbit, like a 100-meter solar array built using advanced laser technology.

    “We’d love to see large-scale structures like satellite antennas, solar panels, space telescopes or even parts of space stations built directly in orbit. This would be a major step toward sustainable space operations and longer missions,” said team member Tianchen Wei, a third-year Ph.D. student in materials science and engineering.

    UF received a $1.1 million DARPA contract to carry out this pioneering research over three phases. While other universities explore various aspects of space manufacturing, UF is the only one specifically focused on laser forming for space applications, Miller said.

    A major challenge of the NOM4D project is overcoming the size and weight limitations of rocket cargo. To address these concerns, Miller’s team is developing laser-forming technology to trace precise patterns on metals to bend them into shape. If executed correctly, the heat from the laser bends the metal without human touch; a key step toward making orbital manufacturing a reality.

    “With this technology, we can build structures in space far more efficiently than launching them fully assembled from Earth,” said team member Nathan Fripp, also a third-year Ph.D. student studying materials science and engineering. “This opens up a wide range of new possibilities for space exploration, satellite systems and even future habitats.”

    Miller said laser bending is complex but getting the correct shape from the metal is only part of the equation.

    “The challenge is ensuring that the material properties stay good or improve during the laser-forming process,” she said. “Can we ensure when we bend this sheet metal that bent regions still have really good properties and are strong and tough with the right flexibility?”

    To analyze the materials, Miller’s students are running controlled tests on aluminum, ceramics and stainless steel, assessing how variables like laser input, heat and gravity affect how materials bend and behave.

    “We run many controlled tests and collect detailed data on how different metals respond to laser energy: how much they bend, how much they heat up, how the heat affects them and more. We have also developed models to predict the temperature and the amount of bending based on the material properties and laser energy input,” said Wei. “We continuously learn from both modeling and experiments to deepen our understanding of the process.”

    The research started in 2021 and has made significant progress, but the technology must be developed further before it’s ready for use in space. This is why collaboration with the NASA Marshall Space Center is so critical. It enables UF researchers to dramatically increase the technology readiness level (TRL) by testing laser forming in space-like conditions inside a thermal vacuum chamber provided by NASA. Fripp leads this testing using the chamber to observe how materials respond to the harsh environment of space.

    “We’ve observed that many factors, such as laser parameters, material properties and atmospheric conditions, can significantly determine the final results. In space, conditions like extreme temperatures, microgravity and vacuums further change how materials behave. As a result, adapting our forming techniques to work reliably and consistently in space adds another layer of complexity,” said Fripp.

    Another important step is building a feedback loop into the manufacturing process. A sensor would detect the bending angle in real time, allowing for feedback and recalibration of the laser’s path.

    As the project enters its final year, finishing in June of 2026, questions remain — especially around maintaining material integrity during the laser-forming process. Still, Miller’s team remains optimistic. UF moves one step closer to a new era of construction with each simulation and laser test.

    “It’s great to be a part of a team pushing the boundaries of what’s possible in manufacturing, not just on Earth, but beyond,” said Wei.

    Continue Reading

  • Critical minerals at a critical moment: Testing the Quad’s resolve

    Critical minerals at a critical moment: Testing the Quad’s resolve

    The Quad Foreign Ministers meeting in Washington this week made one thing clear: the group wants to move from talk to action. That’s a big shift, and a necessary one. But if you look closely at what’s going on behind the scenes, it’s obvious that turning ambition into results won’t be easy.

    Let’s start with comments from US Secretary of State Marco Rubio. He talked about moving beyond “ideas and concepts” and turning the Quad into a “vehicle for action.” That’s not just political theatre. It’s a recognition that the Quad, made up of the United States, Australia, India, and Japan, needs to prove it can actually do things, not just meet and talk. In today’s world, where geopolitical tensions are rising and alliances are being tested, outcomes matter more than ever.

    One of the clearest signs of this new focus is the push to secure critical minerals. This isn’t just about economics, it’s about power. China currently dominates the production and processing of rare earths and other key minerals like lithium, nickel, and copper. That gives Beijing serious leverage, especially in trade talks with the United States. So, when the Quad says it wants to diversify supply chains, it’s not just trying to hedge against market risks – it’s trying to shift the balance of strategic influence.

    There are already some early moves. Japan is investing in Australian mines and refining facilities. Australia has offered the United States preferential access to a planned critical minerals stockpile. But here’s the catch: the US hasn’t taken up that offer yet. That hesitation says a lot about the complicated web of bilateral negotiations that sit underneath the Quad’s big-picture goals.

    And that brings us to the real challenge: the Quad might look united on the surface, but dig a little deeper and you’ll find some serious friction between the United States and its partners.

    If each country is pulling in a slightly different direction, because of domestic politics, economic concerns, or old grievances, it’s going to be hard to deliver on the promises made in Washington.

    Take Australia. There’s still tension over the Trump administration’s trade tariffs and pressure on defence spending. Australia’s offer of minerals access seems to have been ignored so far, and there’s growing anxiety over the AUKUS defence pact, which is currently under review.

    India’s in a similar boat. It’s also been hit by tariffs, and while its External Affairs Minister Subrahmanyam Jaishankar called the meeting “very productive,” he was quick to point out that no relationship is free of issues. India also pushed back on Trump’s claims about intervening in the India-Pakistan conflict – a reminder that trust isn’t automatic, even among allies.

    Then there’s Japan. It’s facing the same tariff pressure and has been asked to ramp up defence spending. That’s already led to the postponement of a key ministerial meeting. Some analysts say the US-Japan relationship has lost momentum, bogged down by trade talks and public disagreements.

    All of this matters because the Quad’s strength depends on its ability to act together. If each country is pulling in a slightly different direction, because of domestic politics, economic concerns, or old grievances, it’s going to be hard to deliver on the promises made in Washington.

    That said, the Quad is clearly trying to broaden its scope. The group is now talking about economic development, tech, supply chains, and maritime security. They even brought in “30 or 40 companies” from member countries to explore private sector partnerships. That’s a smart move, governments can’t do this alone.

    But let’s not forget the bigger picture. The world is still dealing with wars in Ukraine and the Middle East. China’s military rise and its claims on Taiwan are looming large. The Indo-Pacific is a strategic hotspot, and the Quad is trying to navigate it all while keeping its own house in order.

    So yes, the Quad’s commitment to action is real. But the road ahead is messy. If the group can push through its internal tensions and deliver on things like critical minerals, it’ll prove that this alliance isn’t just a talking shop, it’s a force to be reckoned with. That’s a big “if.”

    Continue Reading

  • TET2 mutations in blood stem cells linked to lower Alzheimer’s risk

    TET2 mutations in blood stem cells linked to lower Alzheimer’s risk

    A study published in Cell Stem Cell reveals that some mutations in blood stem cells might help protect against late-onset Alzheimer’s disease.

    A team led by researchers at Baylor College of Medicine discovered that both a mouse model and people carrying blood stem cells with mutations in the gene TET2, but not in the gene DNMT3A, had a lower risk for developing Alzheimer’s disease. Their study proposes a mechanism that can protect against the disease and opens new avenues for potential strategies to control the emergence and progression of this devastating condition.

    “Our lab has long been studying blood stem cells, also called hematopoietic stem cells,” said lead author Dr. Katherine King, professor of pediatrics – infectious diseases and a member of the Center for Cell and Gene Therapy and the Dan L Duncan Comprehensive Cancer Center at Baylor. She also is part of Texas Children’s Hospital.

    Hematopoietic stem cells live in the bone marrow and generate all the different types of blood cells the body needs to stay alive and healthy – red blood cells, immune cells and platelets. As people get older, blood stem cells can develop mutations, and this occurs in about 20% of 70-year-olds. Most of the time, these mutations don’t cause problems, but sometimes, a mutation drives the cells to divide more than others, forming a clone. This process is called clonal hematopoiesis and it has been linked to a higher risk for conditions such as cardiovascular disease, stroke, blood cancers like leukemia and chronic obstructive pulmonary disease. However, many questions remain regarding the connection between clonal hematopoiesis and Alzheimer’s disease.

    “In the current study, we investigated the effect of the two genes most commonly mutated in clonal hematopoiesis, TET2 and DNMT3A, on Alzheimer’s disease,” said first author Dr. Katie A. Matatall, instructor in the King lab. “We also selected these mutations because they are involved in inflammation, which is known to be increased in Alzheimer’s disease.”

    The researchers assessed the effect of clonal hematopoiesis on the prevalence of Alzheimer’s disease using human data stored in the UK Biobank. They also evaluated the role of mutations in genes Tet2 and Dnmt3a in a mouse model of Alzheimer’s disease.

    The team discovered that the two mutations do not behave the same way. Clonal hematopoiesis with the TET2-mutant was associated with a 47% reduced risk of late-onset Alzheimer’s disease in humans, whereas other mutations of clonal hematopoiesis did not confer protection. In a mouse model, transplantation of Tet2-mutant bone marrow reduced cognitive decline and beta-amyloid plaque formation, effects not observed with Dnmt3a-mutant cells.

    “Furthermore, we found that the protective effect seemed to be mediated by TET2-clonal stem cells circulating in the blood,” Matatall said. “Immune cells derived from these clones were able to migrate into the brain where they cleared beta-amyloid deposits, a hallmark of Alzheimer’s disease, more effectively than cells without the TET2 mutation. We think that it’s both the increased migration into the brain and the enhanced ability to clear Alzheimer’s-associated damage that drives the better outcomes.”

    Until now clonal hematopoiesis has primarily been associated with promoting the progression of disease. This is the first time that these two mutations in blood stem cells have been shown to influence disease in different ways. The findings show that some clonal hematopoiesis promote disease while others, like TET2, may provide protection. We need to think about clonal hematopoiesis in a mutation-specific way and assess their risks and benefits.”


    Dr. Katherine King, professor of pediatrics – infectious diseases, Baylor College of Medicine

    The findings establish a novel experimental platform for understanding the role of clonal hematopoiesis in Alzheimer’s disease and may inform future approaches to mitigate the risks of central nervous system degenerative diseases.

    Source:

    Baylor College of Medicine

    Journal reference:

    Matatall, K. A., et al. (2025). TET2-mutant myeloid cells mitigate Alzheimer’s disease progression via CNS infiltration and enhanced phagocytosis in mice. Cell Stem Cell. doi.org/10.1016/j.stem.2025.06.006.

    Continue Reading

  • Air traffic control nightmare looms this summer – POLITICO

    Air traffic control nightmare looms this summer – POLITICO

    “Already last year, the delays in the European aviation network were the worst in 25 years, and the situation this year is likely to deteriorate further,” Transport Commissioner Apostolos Tzitzikostas wrote in a letter to transport ministers in April, seen by POLITICO.

    “Last year, Europe saw 35,000 flights on a busy summer day, this year we expect to reach 38,000,” Tzitzikostas added.

    “High demand puts considerable pressure on Air Navigation Service Providers (ANSPs), some of whom continue to struggle with staff and capacity shortages,” the commissioner acknowledged, calling on governments to start “hiring and training additional controllers where needed.”

    But the problem cannot be solved quickly because training new air traffic controllers takes at least three years. | Thibaud Moritz/AFP via Getty Images

    Calling for more controllers

    But the problem cannot be solved quickly because training new air traffic controllers takes at least three years. On top of that, professional certification to manage air traffic is limited to a specific area of Europe’s fragmented airspace, which is managed by 40 different ANSPs.

    CAE, a Canadian company that specializes in training services, recently forecast that Europe will need the most air traffic controllers of any region over the next decade — 27,000 out of 71,000 globally.

    Meanwhile, airlines are going ballistic.


    Continue Reading

  • Late-Night Cheese May Fuel Nightmares – New Study Explains How – SciTechDaily

    1. Late-Night Cheese May Fuel Nightmares – New Study Explains How  SciTechDaily
    2. ‘Eating habit’ may be key culprit behind sleep disruptions affecting millions of Britons  GB News
    3. Can consuming cheese trigger bad dreams?  India Today
    4. Sweet dreams? No dessert, please: Dairy products tied to nightmares, with riders  Telegraph India
    5. Cheese may really be giving you nightmares, scientists find  Frontiers

    Continue Reading

  • Chinese yuan strengthens to 7.1523 against USD Thursday-Xinhua

    BEIJING, July 3 (Xinhua) — The central parity rate of the Chinese currency renminbi, or the yuan, strengthened 23 pips to 7.1523 against the U.S. dollar Thursday, according to the China Foreign Exchange Trade System.

    In China’s spot foreign exchange market, the yuan is allowed to rise or fall by 2 percent from the central parity rate each trading day.

    The central parity rate of the yuan against the U.S. dollar is based on a weighted average of prices offered by market makers before the opening of the interbank market each business day.

    Continue Reading

  • Kate Middleton opens up about cancer recovery struggles after treatment

    Kate Middleton opens up about cancer recovery struggles after treatment

    Princess of Wales Kate Middleton has spoken candidly about her ongoing struggles following her cancer treatment, admitting that returning to normal life has been more challenging than expected.

    During a visit to Colchester Hospital on July 2, 2025, the 43-year-old royal revealed that although her treatment is complete, the recovery journey has been far from easy. “You put on a sort of brave face, stoicism through treatment,” she shared. “Treatment’s done, then it’s like, ‘I can crack on, get back to normal,’ but actually [that’s not the case].”

    Kate explained that despite being cancer-free and no longer under clinical care, she has found it difficult to function normally at home. She emphasized the importance of support during the post-treatment phase, saying, “Finding a ‘new normal’ takes time. It’s a roller coaster… you go through hard times.”

    Kate first disclosed her cancer diagnosis in March 2024 following abdominal surgery and a temporary break from royal duties. She and Prince William requested privacy during her treatment to protect their children—Prince George, 11, Princess Charlotte, 10, and Prince Louis, 7.

    After completing chemotherapy in September 2024, Kate announced she was cancer-free in early 2025. Since then, she has gradually resumed public appearances, including her participation in Trooping the Colour in June. However, her absence from the Royal Ascot later that month underscored the ongoing challenges in her recovery process.

    Kate remains focused on healing and finding balance as she adjusts to post-treatment life.

    Continue Reading